Target Name: GPC3
NCBI ID: G2719
Other Name(s): Glypican 3, transcript variant 4 | intestinal protein OCI-5 | Glypican-3 (isoform 1) | Glypican 3, transcript variant 2 | Secreted glypican-3 | SGBS1 | SGB | SDYS | secreted glypican-3 | GTR2-2 | SGBS | Glypican 3, transcript variant 1 | GPC3 variant 1 | glypican 3 | GPC3_HUMAN | Glypican-3 alpha subunit | MXR7 | GPC3 variant 2 | Heparan sulphate proteoglycan | glypican proteoglycan 3 | Glypican proteoglycan 3 | Glypican-3 | Intestinal protein OCI-5 | DGSX | Glypican-3 (isoform 4) | heparan sulphate proteoglycan | OCI-5 | Glypican-3 beta subunit | GPC3 variant 4 | Glypican-3 (isoform 2)

GPC3: A Potential Drug Target and Biomarker

GPC3, also known as Glypican 3, is a protein that is expressed in various tissues throughout the body. It is a member of the glypican family, which is a group of extracellular matrix (ECM) proteins that play a crucial role in tissue repair and regeneration. GPC3 is characterized by its unique structure, which consists of a long amino acid sequence that is repeated three times in the middle of the protein.

Recent studies have identified GPC3 as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because GPC3 has been shown to play a role in the development and progression of these diseases. For example, GPC3 has been shown to contribute to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, by promoting the formation of toxic neural cell types.

In addition to its role in disease, GPC3 has also been shown to have potential as a biomarker for various conditions. For example, GPC3 has been used as a biomarker for cancer, as it has been shown to be expressed in the urine and tissue of patients with various types of cancer. Additionally, GPC3 has been shown to be expressed in the brains of patients with neurodegenerative diseases, which suggests that it may have potential as a diagnostic tool for these conditions.

GPC3 has also been shown to have potential as a therapeutic target for various conditions. For example, researchers have shown that inhibiting GPC3 can promote the regression of cancer cells in animal models. Additionally, GPC3 has been shown to be involved in the development of certain autoimmune disorders, which suggests that it may have potential as a therapeutic target for these conditions.

Despite the potential benefits of GPC3 as a drug target and biomarker, much more research is needed to fully understand its role in disease. For example, researchers are still trying to understand the exact mechanism by which GPC3 contributes to disease, as well as the potential benefits and risks of targeting it. Additionally, there are concerns about the potential side effects of targeting GPC3, as some studies have suggested that it may be involved in the development of certain diseases.

In conclusion, GPC3 is a protein that has shown potential as a drug target and biomarker for various diseases. Its unique structure and role in the formation of toxic neural cell types make it an attractive target for researchers to explore. While more research is needed to fully understand its potential, GPC3 is a promising molecule that may have the potential to contribute to the development and treatment of a wide range of conditions.

Protein Name: Glypican 3

Functions: Cell surface proteoglycan (PubMed:14610063). Negatively regulates the hedgehog signaling pathway when attached via the GPI-anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins (By similarity). Binding to the hedgehog protein SHH triggers internalization of the complex by endocytosis and its subsequent lysosomal degradation (By similarity). Positively regulates the canonical Wnt signaling pathway by binding to the Wnt receptor Frizzled and stimulating the binding of the Frizzled receptor to Wnt ligands (PubMed:16227623, PubMed:24496449). Positively regulates the non-canonical Wnt signaling pathway (By similarity). Binds to CD81 which decreases the availability of free CD81 for binding to the transcriptional repressor HHEX, resulting in nuclear translocation of HHEX and transcriptional repression (By similarity). Inhibits the dipeptidyl peptidase activity of DPP4 (PubMed:17549790). Plays a role in limb patterning and skeletal development by controlling the cellular response to BMP4 (By similarity). Modulates the effects of growth factors BMP2, BMP7 and FGF7 on renal branching morphogenesis (By similarity). Required for coronary vascular development (By similarity). Plays a role in regulating cell movements during gastrulation (By similarity)

More Common Targets

GPC4 | GPC5 | GPC5-AS1 | GPC5-AS2 | GPC6 | GPC6-AS1 | GPC6-AS2 | GPCPD1 | GPD1 | GPD1L | GPD2 | GPER1 | GPHA2 | GPHB5 | GPHN | GPI | GPI transamidase complex | GPI-GlcNAc transferase complex | GPIHBP1 | GPKOW | GPLD1 | GPM6A | GPM6B | GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78